Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGenedrive Regulatory News (GDR)

Share Price Information for Genedrive (GDR)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.65
Bid: 1.60
Ask: 1.70
Change: -0.175 (-9.59%)
Spread: 0.10 (6.25%)
Open: 1.825
High: 1.825
Low: 1.65
Prev. Close: 1.825
GDR Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Distribution agreement

9 Mar 2021 07:00

RNS Number : 5536R
Genedrive PLC
09 March 2021
 

 

 

genedrive plc

("genedrive" or the "Company")

 

Genedrive enters distribution agreement with Mountain Horse Solutions

Distribution of genedrive's Military Assays and Instrument in the United States

 

genedrive plc (AIM: GDR), the near patient molecular diagnostics company, announces that it has entered into an agreement for the distribution of the Company's military pathogen detection assays in the United States with Mountain Horse Solutions ("Mountain Horse"), a military contracting specialist to U.S. Federal, State, and Local Government customers.

 

genedrive has a unique product with regard to military CBRNE1 requirements. The Genedrive® BioPlex range of products was developed to the U.S. Department of Defense's (U.S. DoD) product specification with the help of U.S. DoD funding. Designed for field portability and rapid determination of biothreats from pathogens, the Genedrive BioPlex system was developed over a period of five years and has been approved to deployment stage.

 

Contracting with the U.S. Government can be challenging and time consuming. The Company believes that establishing new, local representation in the United States with identified contacts in this highly specialised field will help drive broader product uptake. Organisations like Mountain Horse are already contracted with the U.S. Government, which includes existing framework purchasing agreements, providing an opportunity for more rapid order placement and replenishment of products without the need for new contracts to be negotiated.

 

Bill Allen, President of Mountain Horse Solutions, said: "We are delighted to be working with genedrive with these exciting pathogen detection products. The addition of genedrive's assays to our portfolio of CBRNE mission critical products provides a unique offering of combat-ready sampling and detection devices."

 

David Budd, CEO of genedrive plc, said: "The agreement allows the supply of our BioPlex pathogen detection assays through Mountain Horse, a military contracting specialist who has a number of existing framework contracts with target clients such as the U.S. DoD. We believe that they have both the industry sector knowledge and existing commercial arrangements to increase the exposure of our products and gain new customer opportunities within the various branches and departments of the DoD and U.S. Government."

 

1. Chemical Biological Radiological, Nuclear and Explosive

 

For further details please contact:

 

genedrive plc

+44 (0)161 989 0245

David Budd: CEO / Matthew Fowler: CFO

 

 

 

Peel Hunt LLP (Nominated Adviser and Joint Broker)

+44 (0)20 7418 8900

James Steel / Oliver Jackson

 

 

 

finnCap (Joint Broker)

+44 (0)20 7220 0500

Geoff Nash / Kate Bannatyne / Alice Lane

 

 

 

Walbrook PR Ltd (Media & Investor Relations)

+44 (0)20 7933 8780 or genedrive@walbrookpr.com

Paul McManus / Anna Dunphy

+44 (0)7980 541 893 / +44 (0)7876 741 001

 

 

About genedrive plc (http://www.genedriveplc.com) genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Company has assays on market for the detection of HCV, certain military biological targets, and has tests in development for tuberculosis (mTB). The Company recently released a high throughput SARS-CoV-2 assay and has in development a Genedrive® Point of Care version of the assay, both based on Genedrive® chemistry.

 

About Mountain Horse Solutions 

Mountain Horse Solutions supplies rapid response customized equipment, systems, and training for infectious disease, security, technology, chemical, biological, radiological, nuclear, and explosive (CBRNE) hazards. We specially design innovative solutions, to meet the individual unique threats, needs, and requirements of the military, and first responders. Our team of professionals from around the globe has extensive experience with commercial, DOD, and U.S. Federal Government customers. Mountain Horse Solutions serves organizations, agencies, and contractors worldwide. To find out more visit: www.mtnhorse.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
AGRBIGDXBXGDGBI
Date   Source Headline
5th Jan 201111:41 amRNSDirectors' Shareholdings and Report and Accounts
20th Dec 201011:36 amRNSAdviser - Change of Name
26th Nov 20103:48 pmRNSAGM results
3rd Nov 20107:00 amRNSCommercial Update
5th Oct 20107:00 amRNSFinal Results
4th Oct 201012:07 pmRNSDirector/PDMR Shareholding
10th Aug 201011:12 amRNSHolding(s) in Company
29th Jul 20107:00 amRNSPre close statement
23rd Jul 20101:50 pmRNSHolding(s) in Company
2nd Jul 201010:53 amRNSDirector/PDMR Shareholding
30th Apr 20109:42 amRNSHolding(s) in Company
1st Apr 20107:00 amRNSDirector's Shareholding Update
9th Mar 20107:00 amRNSChange of Adviser
9th Mar 20107:00 amRNSHalf Yearly Report
24th Feb 20109:55 amRNSHalf Yearly Report
4th Jan 20101:43 pmRNSDirector/PDMR Shareholding
9th Dec 20095:09 pmRNSHolding(s) in Company
2nd Dec 20097:00 amRNSResult of AGM
1st Dec 20095:34 pmRNSHolding(s) in Company
1st Dec 20095:33 pmRNSHolding(s) in Company
1st Dec 200911:11 amRNSHolding(s) in Company
30th Nov 20092:50 pmRNSHolding(s) in Company
20th Nov 20098:31 amRNSCash Placing
4th Nov 20092:38 pmRNSPosting of Annual Report and Accounts
23rd Oct 20099:57 amRNSHolding(s) in Company
21st Oct 20094:58 pmRNSHolding(s) in Company
16th Oct 20093:41 pmRNSHolding(s) in Company
12th Oct 20093:10 pmRNSDirector/PDMR Shareholding
6th Oct 20097:30 amRNSFinal Results
1st Oct 20097:00 amRNSDirector/PDMR Shareholding
18th Sep 20099:08 amRNSNotice of Preliminary Results
18th Aug 20093:29 pmRNSAdditional Listing
30th Jul 20097:30 amRNSPre-Close Trading Update
13th Jul 200910:46 amRNSHolding(s) in Company
13th Jul 200910:10 amRNSDirector/PDMR Shareholding
10th Jun 20099:50 amRNSHolding(s) in Company
30th Mar 20093:22 pmRNSDirector Declaration
17th Mar 20095:08 pmRNSAdditional Listing
11th Mar 20097:04 amRNSHalf Yearly Report
2nd Mar 20097:00 amRNSRe Agreement
24th Feb 200911:22 amRNSNotice of Results
5th Dec 20087:30 amRNSAnnual Report and Accounts
28th Nov 20087:30 amRNSChange of Nomad and Adviser
10th Nov 20087:30 amRNSChange of Nomad and Adviser
13th Oct 20088:54 amRNSIssue of Equity & TVR
8th Oct 20083:19 pmRNSChange of Adviser Name
6th Oct 20087:00 amRNSPreliminary Results - October 2008
1st Sep 20087:30 amRNSEPISTEM AND ROTTAPHARM ANNOUN
31st Jul 200811:06 amRNSTrading Update
24th Jul 20088:54 amRNSEPISTEM ANNOUNCE COLLABORATIO

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.